Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Fitstry vs MDLive

Fitstry
Graded #300

Higher grade

vs+2.4000000000000057
MDLive
Graded #357

Lower grade

The verdict

Fitstry takes it — 61.2/100 to 58.8/100.

Fitstry grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Fitstry is the GLP-1 weight-loss program of Weightstry, LLC, a LegitScript-certified, cash-pay telehealth practice focused on women 40+.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMDLive +16
29
45
Dose & formulationFitstry +22
75
53
Clinical oversightMDLive +4
81
85
Labs & monitoringFitstry +19
73
54
FulfillmentFitstry +5
67
62
Contract termsMDLive +8
47
55
Fitstry · left barMDLive · right bar

The numbers

MetricFitstryMDLive
WeighScore61.2/10058.8/100
GradeCC
Scorecard rank#300#357
Semaglutide$179/mo (annual plan, plus a separate fee, compounded)Not disclosed
Tirzepatide$269/mo (annual plan, compounded)Not disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualYesInjection only
Fitstry

Graded #300 · C

Strengths

  • Transparent pricing before you commit — compounded semaglutide from $179/mo, tirzepatide from $269/mo, oral GLP-1 from $209/mo (annual plan)
  • Free screening with a one-time $99 program fee that is fully refunded if a clinician can't prescribe ('Approved, or Your $99 Back')
  • Monthly price bundles a lab panel (CMP, A1c, lipids, TSH), unlimited clinician access, bi-weekly care coaching and a 24/7 Care Line
  • Runs under Weightstry, LLC, a LegitScript-certified practice with an independently verifiable seal, a named support email and phone
  • Full compounded lineup — weekly injection, daily oral tablet and microdosing options

Where it loses points

  • Month-to-month pricing is notably higher than the annual plan ($249 vs $179 semaglutide, $339 vs $269 tirzepatide)
  • Compounded semaglutide and tirzepatide only — no brand-name (Wegovy/Zepbound) options
  • Framed for women 40+, and serves 49 states rather than all 50 (the excluded state isn't disclosed publicly)
  • Works with state-licensed compounding pharmacies but doesn't name a specific pharmacy partner on the Fitstry page
  • Compounded GLP-1s are not FDA-reviewed or approved — a different evidence and regulatory tier than brand-name
MDLive

Graded #357 · C

Strengths

  • Prescribes FDA-approved branded GLP-1s including Wegovy and Zepbound
  • Covered through insurance and employer benefits for 50M-plus people
  • Board-certified physicians averaging about 15 years of experience
  • Part of Evernorth/Cigna, a large established healthcare organization
  • Offers full primary care, not just a single weight-loss funnel

Where it loses points

  • GLP-1s only at clinician discretion in a Primary Care routine visit
  • Anti-obesity meds not available in FL, LA, MS or NJ
  • Distributed mainly via insurers and employers; cost varies by plan
  • No transparent published monthly cash price for GLP-1 care

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard